In July 2018, Petrovax Pharm received Marketing Authorization No. LP-004951 for Grippol® Quadrivalent, a 4-valent inactivated subunit adjuvanted vaccine designed for prevention of influenza. It is the most advanced flu vaccine in the world that employs an antigen sparing technology and has a high preventive activity and safety.

At the sixth annual Russian Pharma Awards 2017, Polyoxidonium, a Russian combination product that is an immunomodulator, detoxifier, and antioxidant, took the prize for «Product of choice for treating and preventing acute viral respiratory infection in children».

Boehringer Ingelheim has concluded phase one of their localization effort aimed at manufacturing their innovative thrombolytic medicines in Russia: the first batches of Metalyse (tenectaplase) for acute heart attack treatment were produced at NPO Petrovax Pharm facilities.

By the end of 2019, the companies intend to complete the transfer of technologies and to launch full-cycle production of innovative thrombolytic medicines at Petrovax Pharm’s production facility in the Moscow Region.